Percheron Therapeutics

Default features description for sign up page.

HOME

INVESTORS

PATIENTS

WHY INVEST

UPDATES

RESEARCH REPORTS

PRESENTATIONS

SHARE PRICE

ASX ANNOUNCEMENTS

ANNUAL REPORTS

PARTNERSHIPS & COLLABORATORS

CORPORATE GOVERNANCE

CORPORATE DIRECTORY

MEET THE TEAM

ABOUT

HMBD-002

PIPELINE

Titillium Web

Managing Director, James Garner provides an update on our new asset - HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator VISTA. 

Percheron Therapeutics Limited (ASX: PER), a biotechnology company focusing on oncology and rare diseases, has released an updated non-confidential corporate presentation. The presentation includes new information on HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator VISTA. The company's financial position is also outlined. HMBD-002 has completed a phase I clinical trial in advanced cancer patients, demonstrating safety and tolerability. Percheron plans to start further clinical trials in 2026. With a strong management team, the company aims to expedite its pipeline progress, potentially generating value-driven news flow in 2026. Investors are invited to ask questions about the presentation or the company's future plans. Percheron has a lean operating model with a focus on R&D, and a market capitalization of AU$12 million. The company is exploring partnerships to advance its novel therapies and capitalize on the emerging field of immuno-oncology. For more information, investors can contact info@PercheronTx.com or visit the company's website. The Board of Directors has authorized this announcement for release to the Australian Securities Exchange. Percheron Therapeutics looks forward to engaging with shareholders and investors.

Percheron Therapeutics Limited Corporate Presentation

Announcement summary